# SOFT (NCT00066690)

> Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

No report yet. It can be ordered.

- Drugs tested: exemestane plus triptorelin; tamoxifen plus triptorelin
- Indication: premenopausal hormone receptor-positive early breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00066690
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: ETOP IBCSG Partners Foundation
- Conditions: Estrogen Receptor Positive Breast Cancer; Progesterone Receptor Positive Tumor; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer
- Interventions: Exemestane; Laboratory Biomarker Analysis; Oophorectomy; Quality-of-Life Assessment; Radiation Therapy; Tamoxifen; Triptorelin
- Enrollment: 3066
- Primary outcome: Disease-free Survival

## Indexed commentary on SOFT so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 164 posts on X
- 60 YouTube videos
- 36 podcast episodes

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=soft-nct00066690

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00066690", "email": "<work email>"}; the inbox owner confirms by the emailed link.
